


Stage IV NSCC: Molecular tests negative (*ALK/BRAF/EGFR/ROS1*)



**Figure 2.** Treatment algorithm for stage IV NSCC, molecular tests negative (*ALK/BRAF/EGFR/ROS1*).

<sup>a</sup>In absence of contraindications and conditioned by the registration and accessibility of anti-PD(L)1 combinations with platinum-based ChT, this strategy will be preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%. Alternatively, if TMB can accurately be evaluated, and conditioned by the registration and accessibility, nivolumab plus ipilimumab should be preferred to platinum-based standard ChT in patients with NSCLC with a high TMB.

<sup>b</sup>Not EMA-approved.